186 related articles for article (PubMed ID: 38542203)
1. Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis.
Yang M; Kamoi K; Zong Y; Zhang J; Zou Y; Ohno-Matsui K
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542203
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis.
Zong Y; Kamoi K; Ando N; Kurozumi-Karube H; Ohno-Matsui K
Front Microbiol; 2022; 13():738742. PubMed ID: 35722286
[TBL] [Abstract][Full Text] [Related]
3. The Anti-Inflammatory Effect of Ripasudil (K-115), a Rho Kinase (ROCK) Inhibitor, on Endotoxin-Induced Uveitis in Rats.
Uchida T; Honjo M; Yamagishi R; Aihara M
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5584-5593. PubMed ID: 29084331
[TBL] [Abstract][Full Text] [Related]
4. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
5. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study.
Futakuchi A; Morimoto T; Ikeda Y; Tanihara H; Inoue T;
Sci Rep; 2020 Jun; 10(1):10308. PubMed ID: 32587304
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
[TBL] [Abstract][Full Text] [Related]
7. Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.
Ohta Y; Takaseki S; Yoshitomi T
Jpn J Ophthalmol; 2017 Sep; 61(5):423-432. PubMed ID: 28653193
[TBL] [Abstract][Full Text] [Related]
8. An update on ripasudil for the treatment of glaucoma and ocular hypertension.
Testa V; Ferro Desideri L; Della Giustina P; Traverso CE; Iester M
Drugs Today (Barc); 2020 Sep; 56(9):599-608. PubMed ID: 33025953
[TBL] [Abstract][Full Text] [Related]
9. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
Inoue T; Tanihara H
Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
[TBL] [Abstract][Full Text] [Related]
10. A Rho-Associated Kinase Inhibitor Protects Permeability in a Cell Culture Model of Ocular Disease, and Reduces Aqueous Flare in Anterior Uveitis.
Yamada H; Yoneda M; Inaguma S; Gosho M; Murasawa Y; Isogai Z; Zako M
J Ocul Pharmacol Ther; 2017 Apr; 33(3):176-185. PubMed ID: 28157424
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
[TBL] [Abstract][Full Text] [Related]
13. Identification of Nitric Oxide-Donating Ripasudil Derivatives with Intraocular Pressure Lowering and Retinal Ganglion Cell Protection Activities.
Yang Z; Wu J; Wu K; Luo J; Li C; Zhang J; Zhao M; Mei T; Liu X; Shang B; Zhang Y; Zhao L; Huang Z
J Med Chem; 2022 Sep; 65(17):11745-11758. PubMed ID: 36007247
[TBL] [Abstract][Full Text] [Related]
14. Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells.
Okumura N; Okazaki Y; Inoue R; Nakano S; Fullwood NJ; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7560-7. PubMed ID: 26618648
[TBL] [Abstract][Full Text] [Related]
15. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts.
Futakuchi A; Inoue T; Fujimoto T; Inoue-Mochita M; Kawai M; Tanihara H
Exp Eye Res; 2016 Aug; 149():107-115. PubMed ID: 27394186
[TBL] [Abstract][Full Text] [Related]
16. Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T-cell leukemia virus type-1 uveitis. Accumulation of the human T-cell leukemia virus type-1-infected cells and constitutive expression of viral and interleukin-6 messenger ribonucleic acids.
Ono A; Mochizuki M; Yamaguchi K; Miyata N; Watanabe T
Invest Ophthalmol Vis Sci; 1997 Mar; 38(3):676-89. PubMed ID: 9071222
[TBL] [Abstract][Full Text] [Related]
17. HTLV-1 uveitis.
Kamoi K; Mochizuki M
Front Microbiol; 2012; 3():270. PubMed ID: 22837757
[TBL] [Abstract][Full Text] [Related]
18. Ripasudil: first global approval.
Garnock-Jones KP
Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
[TBL] [Abstract][Full Text] [Related]
19. Ripasudil Attenuates Lipopolysaccharide (LPS)-Mediated Apoptosis and Inflammation in Pulmonary Microvascular Endothelial Cells via ROCK2/eNOS Signaling.
Yang J; Ruan F; Zheng Z
Med Sci Monit; 2018 May; 24():3212-3219. PubMed ID: 29766980
[TBL] [Abstract][Full Text] [Related]
20. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
